These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6094274)

  • 21. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
    Komanicky P; Spark RF; Melby JC
    J Clin Endocrinol Metab; 1978 Nov; 47(5):1042-51. PubMed ID: 233687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical results of the use of mitotane for adrenocortical carcinoma.
    Kasperlik-Zaluska AA
    Braz J Med Biol Res; 2000 Oct; 33(10):1191-6. PubMed ID: 11004719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
    Verhelst JA; Trainer PJ; Howlett TA; Perry L; Rees LH; Grossman AB; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):169-78. PubMed ID: 1657460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
    Lim MC; Tan YO; Chong PY; Cheah JS
    Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)].
    Knappe G; Gerl H; Ventz M; Rohde W
    Dtsch Med Wochenschr; 1997 Jul; 122(28-29):882-6. PubMed ID: 9264918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma pregnenolone and 17-OH-pregnenolone in patients with adrenal tumors, ACTH excess, or idiopathic hirsutism.
    McKenna TJ; Miller RB; Liddle GW
    J Clin Endocrinol Metab; 1977 Feb; 44(2):231-6. PubMed ID: 190251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report.
    Naruse T; Koike A; Kato K; Ishii T; Suzumura K; Matsumoto K
    Endocrinol Jpn; 1984 Aug; 31(4):417-26. PubMed ID: 6097439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The organochlorine o,p'-DDD disrupts the adrenal steroidogenic signaling pathway in rainbow trout (Oncorhynchus mykiss).
    Lacroix M; Hontela A
    Toxicol Appl Pharmacol; 2003 Aug; 190(3):197-205. PubMed ID: 12902190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Multiple recurrence of Cushing's syndrome after bilateral adrenalectomy and pituitary gland surgery. Cure with o,p'-DDD].
    Bigler U; Müller J
    Schweiz Med Wochenschr; 1978 Jan; 108(2):67-72. PubMed ID: 622536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.
    Engelhardt D; Jacob K; Doerr HG
    Klin Wochenschr; 1989 Feb; 67(4):241-7. PubMed ID: 2538676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Agents inhibiting steroid biosynthesis--aminoglutethimide and o,p'-DDD].
    Aida M; Miura K
    Nihon Rinsho; 1974 Nov; 32(11):3257-61. PubMed ID: 4375206
    [No Abstract]   [Full Text] [Related]  

  • 33. Response of plasma adrenal steroids to synthetic ACTH under ketoconazole in man.
    Yamakita N; Yasuda K; Murase H; Murayama M; Goshima E; Hirai M; Noritake N; Takeda N; Miura K
    Endocrinol Jpn; 1987 Feb; 34(1):29-35. PubMed ID: 3038504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
    Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
    Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.
    Moolenaar AJ; van Slooten H; van Seters AP; Smeenk D
    Cancer Chemother Pharmacol; 1981; 7(1):51-4. PubMed ID: 7340988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of adrenal cortical secretion by amino-glutethimide in dogs.
    Wilroy RS; Camacho AM; Trouy RL; Hagen AA
    Endocrinology; 1968 Jul; 83(1):56-60. PubMed ID: 4298186
    [No Abstract]   [Full Text] [Related]  

  • 37. [Use of mitotane (o,p'-DDD) in adrenal cortex hyperfunction].
    Kasperlik-Załuska A; Migdalska B
    Endokrynol Pol; 1982; 33(1-3):99-104. PubMed ID: 7183447
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma steroid dynamics in Cushing's syndrome.
    Luisi M; Franchi F; Drafta D; Stroe E
    Ann Endocrinol (Paris); 1978; 39(2):107-15. PubMed ID: 686649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of adrenal autonomy in Cushing's syndrome: a comparison between in vivo and in vitro responsiveness of the adrenal gland.
    Lamberts SW; Zuiderwijk J; Uitterlinden P; Blijd JJ; Bruining HA; de Jong FH
    J Clin Endocrinol Metab; 1990 Jan; 70(1):192-9. PubMed ID: 2152930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.